Fig. 5
MAO-B-positive mitovesicles are more numerous in the brain than MAO-A-positive mitovesicles. (A, B) Representative flow cytometry analyses of Fr8 brain EVs (mitovesicle-enriched, second columns) immunolabeled with antibodies against MAO-A (A) and MAO-B (B). The left columns show the same analyses performed on a 1:1:1 v/v mixture of Fr1, Fr2, and Fr3 EVs (microvesicle-enriched) isolated from the same brains (negative control). The right columns show mitovesicles incubated with the secondary antibody only. The gating strategy is shown for all conditions (first rows). Both the y- and the x-axis are in a log10 scale. 20,000 EVs were acquired for each experiment. FSC-A: forward scatter– area. SSC-A: side scatter– area. Ab: antibody. (C) Percentage of mitovesicles positive for either MAO-A or MAO-B. n = 3 mice per group. The percentage of positive EVs was determined on the basis of the secondary antibody control gate of each sample (set to 0.8% maximum). Bars: mean ± SEM. Statistical test used: two-tailed, unpaired Student’s t-test. MAO-A vs. MAO-B, P = 0.0004. *** P < 0.001